Table 1.
The Role of iNOS and NADPH Oxidase in Mediating Tumor Rejection in Response to B16-GM-CSF Vaccination
| WT no vaccine | NOS−/− no vaccine | WT B16-GM-CSF | NOS−/− B16-GM-CSF | |||||
|---|---|---|---|---|---|---|---|---|
| Exp. 1 | 0/5 (0%) | 0/5 (0%) | 10/10 (100%) | 6/10 (60%) | ||||
| Exp. 2 | 0/5 (0%) | 0/5 (0%) | 9/10 (90%) | 5/10 (50%) | ||||
| WT no vaccine | X-CGD no vaccine | WT B16-GM-CSF | X-CGD B16-GM-CSF | |||||
| Exp. 1 | 0/5 (0%) | 0/5 (0%) | 8/10 (80%) | 3/10 (30%) | ||||
| Exp. 2 | 0/5 (0%) | 0/5 (0%) | 8/10 (80%) | 3/10 (30%) | ||||
| Exp. 3 | 0/5 (0%) | 0/5 (0%) | 9/10 (90%) | 4/10 (40%) |
Wild-type (WT), iNOS−/−, and X-CGD C57BL/6 mice were injected subcutaneously in the left flank with 106 irradiated (50 Gy) BI6-GM-CSF cells. Mice were challenged 2 wk later in the right flank with 105 live B16-WT cells. Results are presented as number of tumor free survivors after 8 wk over the total number of mice. P = 0.0084 by two-sided Fisher's exact test comparing vaccinated wild-type and NOS−/− mice. Fisher's exact test (rather than the χ2 test) was used to test the difference in the proportion of tumor-free survivors comparing vaccinated wild-type versus NOS−/− mice because of the small numbers of expected and observed vaccinated wild-type mice that developed tumors. The test suggests a significant difference between the proportion of tumor-free survivors in the wild-type and NOS−/− mice (P = 0.0084), with an odds ratio of 15.54 (95% confidence interval: 1.73–139.65 using Woolf's procedure). P = 0.001 by χ2 test comparing vaccinated wild-type and X-CGD mice.